HIV vaccine - AVANT

Drug Profile

HIV vaccine - AVANT

Alternative Names: HIV-Therapore™ Vaccine

Latest Information Update: 02 Aug 2006

Price : $50

At a glance

  • Originator AVANT Immunotherapeutics; Walter Reed Army Institute of Research
  • Developer Celldex Therapeutics Inc; Walter Reed Army Institute of Research
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Cancer; HIV infections

Most Recent Events

  • 13 May 2004 Phase-I clinical trials in HIV infections treatment in USA (unspecified route)
  • 17 Jun 2002 This vaccine is still in active development
  • 05 Apr 2002 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top